Combining the test results of molecular docking between SeSA-DCA and CDC25A (Figure 6G), we have concluded that SeSA-DCA can inhibit the expression of CDC25A not only by direct interaction with it but also by regulation of HDAC1, therefore causing the cell cycle arrest of prostate cancer cells and impeding their proliferation. The gene discussed is CDC25A; the disease is prostate carcinoma.